Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-108 in Advanced Solid Tumors
NCT05518045Phase 2Active, not recruiting
- Sponsor
- LaNova Medicines
- Start
- Aug 2022
- Primary completion
- Oct 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of LM-108 in solid tumor (advanced stage), sponsored by LaNova Medicines. Started Aug 2022; status: active, not recruiting.
02
Drugs
LM-108
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05518045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05518045.